Biogen: Affinity: Multiple Sclerosis
An 18-month placebo controlled monthly IV study to evaluate an add on therapy for Relapsing Remitting or Secondary Progressive MS, must be 18-58 years of age, and be treated with one of the following DMTs for 6 months prior to baseline: Avonex, Plegridy, Betaseron, Rebif, Techfidera or Tysabri-Subjects will continue on their current therapy throughout the study. A relapse or new lesion (enhancing or T2) within the last 24 months is also part of inclusion criteria.

Novartis-COMB: Multiple Sclerosis
A 2-year study for Multiple Sclerosis to evaluate an investigational monthly IV medication vs. Teriflunomide. Participants must be 18-55 years of age, with Relapsing Remitting or Secondary progressive MS.

Novartis-FLUENT: Multiple Sclerosis
A 1 year observational study for patients either taking Gilenya for 2 consecutive years or newly prescribed. Only blood draws and questionnaires required.

To participate or refer a patient --Call 954-475-8171 Ext 134 (Michele)